Julphar Signs Deal To Complete Insulin Production

BMI View: Despite the shortcomings of low growth for the UAE pharmaceutical market in the long run, there are opportunities in the chronic disease field, in line with Middle Eastern trends for diabetes and hypertensive disorders. Generic drugmakers operating in the country will be restricted to this segment, along with essential medicines, and we therefore believe that the UAE will form a manufacturing and research and development (R&D) base for drugmakers looking for entry into the Middle East.

To read the full article, please choose one of the following options: